Nanology LLC's strategy is "almost like having a new molecular entity, in terms of the broadness of the intellectual property [IP] around it, but on a more streamlined path to potential approval" if safety and efficacy pan out, Marc Iacobucci, managing director of DFB Pharmaceuticals Inc. told BioWorld, with a nod to the 505(b)(2) regulatory pathway that the Fort Worth, Texas-based firm intends to trod.